Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.72 | N/A | +3.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.72 | N/A | +3.15% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized ongoing efforts to meet market demands.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and addressing market needs.
Pfizer's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock declined by 1.29% on the day, likely due to the lack of revenue data and forward guidance, which may have left investors uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SAP SE ADR
Oct 26, 2020